The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Whilst never been carried away with all the hype and sheer desperation clouding sensible judgement as to how this will play out I am genuinely confused as to why we are where we are in terms of share price.
I get the funding issue going forward and the fact that we are still early stage in clinical trials but I would have thought the risk reward balance would have meant a higher market cap for the company and therefore higher share price.
Happy New Year and let’s see if 2024 brings an uptick in this companies share price and ultimately their search for a cancer cure.
This RNS is certainly good news for investors as it is the speeding up of the pathway to funding for the platform through to completion . I think the market will react positively.
As I said the other day AS is not a fool . You don’t build up a business from scratch to be worth millions cos you are clueless. As with everything patience is a virtue!
Honestly just read the postings on this board from the majority of posters. You all think you can do a better job than the CEO. You are all giving him advice of how to run the company , what he’s done wrong and what he can do to put things right , what he needs to do going forward and when he needs to raise money. Have any of you guys started up a company from nothing and it’s now worth plus £250m ? No thought not you haven’t got the guts, belief, skills or determination required to succeed so instead you jump on the back of someone who has done it and try to tell him how to do it. Leave him to run the business and you all concentrate on dreaming how one day this guy might make you wealthier than you are now.
Just another question why if the data is absolutely on the mark as described by AS and the. Oncology experts has this firm not been bought out yet? Could it possibly be that BP are waiting for published data independently reviewed !